S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
NASDAQ:ORGO

Organogenesis (ORGO) Stock Price, News & Analysis

$3.46
+0.07 (+2.06%)
(As of 02/23/2024 ET)
Today's Range
$3.30
$3.48
50-Day Range
$3.20
$4.49
52-Week Range
$1.79
$4.70
Volume
414,765 shs
Average Volume
468,603 shs
Market Capitalization
$456.86 million
P/E Ratio
34.60
Dividend Yield
N/A
Price Target
$4.83

Organogenesis MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
39.7% Upside
$4.83 Price Target
Short Interest
Bearish
8.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.01
Upright™ Environmental Score
News Sentiment
0.00mentions of Organogenesis in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$864,915 Sold Last Quarter
Proj. Earnings Growth
20.00%
From $0.05 to $0.06 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.35 out of 5 stars

Medical Sector

114th out of 941 stocks

Pharmaceutical Preparations Industry

40th out of 432 stocks


ORGO stock logo

About Organogenesis Stock (NASDAQ:ORGO)

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary wound covering; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly AM, PuraPly XT, and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

ORGO Stock Price History

ORGO Stock News Headlines

Organogenesis (ORGO) Set to Announce Earnings on Thursday
Organogenesis Holdings Inc - Ordinary Shares - Class A
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
3 Biotech Stocks Flowing With Investment Potential
Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results
Organogenesis jumps after Medicare policy update
BTIG Sticks to Their Buy Rating for Organogenesis Holdings (ORGO)
See More Headlines
Receive ORGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/23/2024
Next Earnings (Confirmed)
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORGO
Fax
N/A
Employees
1,030
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.83
High Stock Price Target
$6.00
Low Stock Price Target
$3.50
Potential Upside/Downside
+39.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$15.53 million
Pretax Margin
4.66%

Debt

Sales & Book Value

Annual Sales
$450.89 million
Cash Flow
$0.26 per share
Book Value
$2.03 per share

Miscellaneous

Free Float
87,147,000
Market Cap
$456.86 million
Optionable
Optionable
Beta
1.59
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report














ORGO Stock Analysis - Frequently Asked Questions

Should I buy or sell Organogenesis stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ORGO shares.
View ORGO analyst ratings
or view top-rated stocks.

What is Organogenesis' stock price target for 2024?

3 Wall Street analysts have issued twelve-month target prices for Organogenesis' shares. Their ORGO share price targets range from $3.50 to $6.00. On average, they anticipate the company's share price to reach $4.83 in the next twelve months. This suggests a possible upside of 39.7% from the stock's current price.
View analysts price targets for ORGO
or view top-rated stocks among Wall Street analysts.

How have ORGO shares performed in 2024?

Organogenesis' stock was trading at $4.09 at the beginning of the year. Since then, ORGO stock has decreased by 15.4% and is now trading at $3.46.
View the best growth stocks for 2024 here
.

When is Organogenesis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 29th 2024.
View our ORGO earnings forecast
.

How can I listen to Organogenesis' earnings call?

Organogenesis will be holding an earnings conference call on Thursday, February 29th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc. (NASDAQ:ORGO) announced its quarterly earnings results on Tuesday, November, 9th. The company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. The business had revenue of $113.75 million for the quarter, compared to analysts' expectations of $112.10 million. Organogenesis had a trailing twelve-month return on equity of 4.83% and a net margin of 2.90%. During the same quarter in the previous year, the company posted $0.19 earnings per share.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis updated its FY 2023 earnings guidance on Monday, December, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $433.0 million-$446.0 million, compared to the consensus revenue estimate of $437.9 million.

What other stocks do shareholders of Organogenesis own?
Who are Organogenesis' major shareholders?

Organogenesis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.06%), Dimensional Fund Advisors LP (1.05%), Charles Schwab Investment Management Inc. (0.63%), Northern Trust Corp (0.47%), Norges Bank (0.37%) and Thompson Siegel & Walmsley LLC (0.32%). Insiders that own company stock include 2016 Organo 10-Year Grat U/ Gn, Albert Erani, Antonio S Montecalvo, Arthur S Leibowitz, Dennis Erani, Gary S Gillheeney, Gary S Gillheeney, Glenn H Nussdorf, Michael W Katz, Michael W Katz and Starr Wisdom.
View institutional ownership trends
.

How do I buy shares of Organogenesis?

Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ORGO) was last updated on 2/24/2024 by MarketBeat.com Staff